NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Operating Income : $-175.11 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Operating Income?

NewAmsterdam Pharma Co NV's Operating Income for the six months ended in Dec. 2023 was $-95.40 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-175.11 Mil.

Warning Sign:

NewAmsterdam Pharma Co NV had lost money in 67% of the time over the past 3quarters.

Operating Margin % is calculated as Operating Income divided by its Revenue. NewAmsterdam Pharma Co NV's Operating Income for the six months ended in Dec. 2023 was $-95.40 Mil. NewAmsterdam Pharma Co NV's Revenue for the six months ended in Dec. 2023 was $3.70 Mil. Therefore, NewAmsterdam Pharma Co NV's Operating Margin % for the quarter that ended in Dec. 2023 was -2,579.02%.

NewAmsterdam Pharma Co NV's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NewAmsterdam Pharma Co NV's annualized ROC % for the quarter that ended in Dec. 2023 was -286.58%. NewAmsterdam Pharma Co NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -170,936.32%.

NewAmsterdam Pharma Co NV Operating Income Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Operating Income Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Income

-6.49

-34.65

1.94

-175.11

NewAmsterdam Pharma Co NV Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Income	Get a 7-Day Free Trial			-22.98	57.71	-55.77	-79.71	-95.40

NewAmsterdam Pharma Co NV Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-175.11 Mil.

NewAmsterdam Pharma Co NV (NAS:NAMS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NewAmsterdam Pharma Co NV's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-190.796 * ( 1 - -0.03% )	/	( (107.93	+	25.266)	/ 2 )
=	-190.8532388	/	66.598
=	-286.58 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	511.963	-	22.663	-	( 416.761	-	max(0, 41.66	-	423.03	+	416.761	))
=	107.93

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	347.097	-	24.937	-	( 340.45	-	max(0, 49.897	-	346.791	+	340.45	))
=	25.266

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

NewAmsterdam Pharma Co NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-190.594	/	( ( (0.122 + max(-41.59, 0))	+	(0.101 + max(-45.377, 0)) )	/	2 )
=	-190.594	/	( ( 0.122	+	0.101 )	/	2 )
=	-190.594	/	0.1115
=	-170,936.32 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	-5.6843418860808E-14)	-	(22.663	+	10.531	+	8.396)
=	-41.59

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.46)	-	(24.937	+	8.942	+	15.958)
=	-45.377

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

NewAmsterdam Pharma Co NV's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-95.398	/	3.699
	=	-2,579.02 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

NewAmsterdam Pharma Co NV Operating Income Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.